Kewaunee Scientific Co. (NASDAQ:KEQU) CEO Sells $59,819.36 in Stock

Kewaunee Scientific Co. (NASDAQ:KEQU - Get Free Report) CEO Thomas David Hull III sold 1,844 shares of Kewaunee Scientific stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $32.44, for a total transaction of $59,819.36. Following the transaction, the chief executive officer now directly owns 36,072 shares in the company, valued at approximately $1,170,175.68. This trade represents a 4.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Thomas David Hull III also recently made the following trade(s):

• On Monday, March 24th, Thomas David Hull III sold 3,000 shares of Kewaunee Scientific stock. The shares were sold at an average price of $45.63, for a total value of $136,890.00.
• On Friday, March 21st, Thomas David Hull III sold 213 shares of Kewaunee Scientific stock. The shares were sold at an average price of $48.53, for a total value of $10,336.89.

Kewaunee Scientific Stock Down 2.5 %

KEQU stock traded down $0.85 during trading on Friday, reaching $33.44. The stock had a trading volume of 9,461 shares, compared to its average volume of 23,881. Kewaunee Scientific Co. has a 1-year low of $30.82 and a 1-year high of $71.33. The company has a market capitalization of $95.47 million, a P/E ratio of 5.30 and a beta of 0.59. The company has a current ratio of 2.64, a quick ratio of 2.13 and a debt-to-equity ratio of 0.45. The firm has a fifty day moving average price of $46.51 and a 200 day moving average price of $47.27.

Kewaunee Scientific (NASDAQ:KEQU - Get Free Report) last issued its quarterly earnings data on Wednesday, March 12th. The technology company reported $1.09 earnings per share for the quarter. Kewaunee Scientific had a return on equity of 25.83% and a net margin of 9.39%. The firm had revenue of $67.17 million during the quarter.

Analyst Ratings Changes

Separately, StockNews.com downgraded shares of Kewaunee Scientific from a "buy" rating to a "hold" rating in a research report on Friday, March 14th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE raised its stake in shares of Kewaunee Scientific by 2,605.9% in the 4th quarter. Bank of America Corp DE now owns 460 shares of the technology company's stock valued at $28,000 after purchasing an additional 443 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Kewaunee Scientific by 18,000.0% during the third quarter. JPMorgan Chase & Co. now owns 905 shares of the technology company's stock valued at $30,000 after buying an additional 900 shares in the last quarter. IFP Advisors Inc bought a new position in Kewaunee Scientific during the 4th quarter worth approximately $36,000. Morgan Dempsey Capital Management LLC acquired a new position in shares of Kewaunee Scientific in the 4th quarter worth approximately $106,000. Finally, Barclays PLC bought a new stake in shares of Kewaunee Scientific in the 3rd quarter valued at approximately $121,000. 32.69% of the stock is currently owned by institutional investors.

About Kewaunee Scientific

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.